EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

SGLT2i use and fracture risk compared with DPP4i in patients with T2DM

Sung-Yen Lin iD, Shih-Hao Huang iD, Ching-Han Chiang, Cheng-Jung Ho, Chung-Hwan Chen iD, Li-Nien Chien iD

Journal of Diabetes Investigation · 2026-11 · 17 (11) · 1927-1937

DOI: 10.1111/jdi.70433 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 16.09.2026. Verfasst von Sung-Yen Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fractures, Bone, Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The association between sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) use and fracture risk remains inconclusive. Most previous studies have focused on treatment‐naïve patients, despite many patients in routine clinical practice initiating SGLT2i therapy after prior dipeptidyl peptidase‐4 inhibitor (DPP4i) use. This study aimed to evaluate the risk of fractures associated with SGLT2i compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) in Taiwan. Materials and Methods This nationwide cohort study used Taiwan's National Health Insurance Research Database. Patients with T2DM initiating SGLT2i or DPP4i therapy between 2016 and 2019 were identified. Follow‐up began one year after the index date to ensure adequate treatment exposure before outcome assessment. A prevalent new‐user design and 1:2 propensity score matching (PSM) were applied to balance baseline characteristics. Fractures were ascertained from medical claims, and competing risk regression was used to estimate fracture risk, accounting for death as a competing event.

Results

After PSM, 106,992 SGLT2i users and 213,984 DPP4i users were included with comparable baseline profiles. Over a mean follow‐up of 3.5 years, the overall risk of any fracture did not differ between groups. Although SGLT2i use was associated with a significantly lower risk of hip fracture compared with DPP4i use (subdistribution hazard ratio = 0.89, 95% CI: 0.81–0.98), this association was no longer statistically significant after adjustment for multiple comparisons. Subgroup analyses yielded generally consistent findings.

Conclusions

In this cohort, SGLT2i use was not associated with increased overall or major osteoporotic fracture risk vs DPP4i. The prevalent new‐user design captures prior treatment histories and reflects real‐world practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fractures, BoneDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsHumansFemaleMaleTaiwanMiddle AgedAgedFollow-Up StudiesRisk FactorsPrognosis

Stichwörter der Autor:innen

SGLT2iT2DMfracture risk

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Orthopedics, Kaohsiung Medical University Gangshan Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Division of Adult Reconstruction Surgery, Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Orthopaedic Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

ORCID-Profile: Sung-Yen Lin, Shih-Hao Huang, Chung-Hwan Chen, Li-Nien Chien

Förderung

  • National Science and Technology Council

Zitieren

APA

Lin, S. Y., Huang, S. H., Chiang, C. H., Ho, C. J., Chen, C. H., & Chien, L. N. (2026). SGLT2i use and fracture risk compared with DPP4i in patients with T2DM. Journal of Diabetes Investigation, 17(11), 1927-1937. https://doi.org/10.1111/jdi.70433

Vancouver

Lin SY, Huang SH, Chiang CH, Ho CJ, Chen CH, Chien LN. SGLT2i use and fracture risk compared with DPP4i in patients with T2DM. Journal of Diabetes Investigation. 2026;17(11):1927-1937. doi:10.1111/jdi.70433

BibTeX
@article{Lin2026,
  author = {Lin, Sung-Yen and Huang, Shih-Hao and Chiang, Ching-Han and Ho, Cheng-Jung and Chen, Chung-Hwan and Chien, Li-Nien},
  title = {SGLT2i use and fracture risk compared with DPP4i in patients with T2DM},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  volume = {17},
  number = {11},
  pages = {1927--1937},
  doi = {10.1111/jdi.70433}
}
Kostenlos starten →